| Name | Title | Contact Details |
|---|
UC San Diego Health Sciences has long been known as a place where discoveries are made. Today, we are known as a place where discoveries are delivered. UC San Diego Health Sciences encompasses the School of Medicine, the Skaggs School of Pharmacy and Pharmaceutical Sciences, and UC San Diego Health System, including UC San Diego Medical Center, in Hillcrest; and in La Jolla, Thornton Hospital, Moores Cancer Center, Sulpizio Cardiovascular Center; and other centers, primary and specialty practices of the UC San Diego Medical Group faculty physicians. As a top-tier academic medical center, its role is to provide leadership in improving health through research, education and patient care. UC San Diego Health Sciences has long been at the forefront of “bench-to-bedside” research, transforming patient care through discovery and innovation leading to new drugs and technologies. It is carried out every day in the hundreds of clinical trials of promising new therapies offered through UC San Diego Health System, and in the drive of our researchers and clinician-scientists who are committed to having a significant impact on patient care. At UC San Diego Health Sciences, there are many discoveries on our horizon. Our commitment is to continue our quest to cure disease, seek better treatments and train the next generation of physicians and scientists.
Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry™. Protein Medicinal Chemistry™ can optimize any protein or antibody to create potentially best-in-class therapeutics such as long-acting proteins, bi-specifics and antibody drug conjugates. The Ambrx advantage allows us to safely and effectively target cytotoxic agents or recruit effector function to tumor cells (oncology) or modulate biological pathways implicated in disease areas such as autoimmune, metabolic and cardiovascular. At Ambrx, we are dedicated to assembling and developing an exceptional team and a novel technology to create the next generation of protein-based medicines.
Bio-Tissue®, a subsidiary of TissueTech™, is the leader in regenerative biologic therapies and ocular hygiene solutions for eye care professionals. Established in 1997, Bio-Tissue® serves an unmet need for better surgical and therapeutic alternatives for helping eye care professionals heal ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis dry eye, pterygium and dry eye. Eye care professionals understand that good medicine is based on good science. Bio-Tissue® prides itself on developing products that meet the highest clinical standards, are based on quality research and scientific data, and provide innovative solutions for a range of ocular surface and lid margin diseases. Bio-Tissue® adheres to the FDA tissue and medical device guidelines.
Informatics Corporation of America is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Axess Ultrasound is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.